儿童急性髓系白血病原发性耐药病的特征与结局
该研究基于NOPHO-AML 93、NOPHO-AML 2004、DB AML-01和NOPHO-DBH AML 2012方案注册治疗的1013例儿童急性髓系白血病(AML)患者,分析其中66例原发耐药病(RD)患者的临床与生物学特征。RD的危险因素为年龄≥10岁及诊断时白细胞计数≥100×10^9/L。5年总生存(OS)为38%(95%CI:28%-52%)。
要点
- 原发耐药病危险因素为年龄≥10岁及诊断时WBC≥100×10^9/L。
- 66例RD患者5年OS为38%(95%CI:28%-52%)。
- 获CR后行HSCT者OS为56%(95%CI:41%-77%,N=30)。
核心结论
- 近40%的原发耐药儿童AML患者可通过挽救化疗后行异基因造血干细胞移植(HSCT)获得治愈。
- 两个挽救化疗疗程后未达完全缓解(CR)的儿童未能从额外化疗中获益。
研究设计与样本
- 研究纳入按NOPHO-AML 93、NOPHO-AML 2004、DB AML-01和NOPHO-DBH AML 2012方案注册并治疗的1013例儿童AML患者,其中66例为原发耐药病(RD)。
主要发现
- RD的危险因素为年龄≥10岁和诊断时白细胞计数≥100×10^9/L。
- 66例RD患者的5年总生存(OS)为38%(95%CI:28%-52%)。
- 63例接受化疗挽救治疗的儿童中,59%(N=37)达到完全缓解(CR),其OS为57%(95%CI:42%-75%);未达CR者OS为12%(95%CI:4%-35%)。
- 给予超过两个挽救化疗疗程未提高CR率。
- 所有43例接受异基因HSCT的患者OS为49%(95%CI:36%-66%);达到CR并接受HSCT者(N=30)OS为56%(95%CI:41%-77%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A significant proportion of events in paediatric acute myeloid leukaemia (AML) are caused by resistant disease (RD). We investigated clinical and biological characteristics in 66 patients with RD from 1013 children with AML registered and treated according to the NOPHO-AML 93, NOPHO-AML 2004, DB AML-01 and NOPHO-DBH AML 2012 protocols. Risk factors for RD were age10 years or older and a white-blood-cell count (WBC) of 100 × 109 /L or more at diagnosis. The five-year overall survival (OS) was 38% (95% confidence interval [CI]: 28%-52%). Of the 63 children that received salvage therapy with chemotherapy, 59% (N = 37) achieved complete remission (CR) with OS 57% (95% CI: 42%-75%) compared to 12% (95% CI: 4%-35%) for children that did not achieve CR. Giving more than two salvage chemotherapy courses did not increase CR rates. OS for all 43 patients receiving allogeneic haematopoietic stem cell transplantation (HSCT) was 49% (95% CI: 36%-66%). Those achieving CR and proceeding to HSCT had an OS of 56% (95% CI: 41%-77%, N = 30). This study showed that almost 40% of children with primary resistant AML can be cured with salvage therapy followed by HSCT. Children that did not achieve CR after two salvage courses with chemotherapy did not benefit from additional chemotherapy.
引用
- Karlsson L, Cheuk D, De Moerloose B, et al. Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia. Br J Haematol. 2023. PMID: 36762836. doi:10.1111/bjh.18685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。